Natera's Prospera Test Validated Across 17 Studies at ISHLT 2026
Event summary
- Natera presented data from 17 abstracts at ISHLT 2026, including six oral presentations.
- Prospera Heart predicted adverse outcomes in heart transplant patients with up to 4x higher risk.
- Prospera Lung detected infection, CLAD, and graft damage not visible on biopsy.
- Real-world data showed Prospera influenced physician decisions in over 30% of cases.
The big picture
Natera's strong showing at ISHLT 2026 underscores the growing clinical validation of Prospera in heart and lung transplantation. The data reinforces its role in early detection, risk stratification, and treatment decision-making, positioning it as a key player in precision medicine for organ health. With over 400 peer-reviewed publications supporting its tests, Natera continues to solidify its market position in cell-free DNA diagnostics.
What we're watching
- Clinical Adoption
- How the real-world impact data will accelerate Prospera's integration into standard transplant care protocols.
- Competitive Positioning
- Whether Natera can sustain its leadership in cell-free DNA diagnostics amid growing competition.
- Regulatory Pathways
- The pace at which Prospera gains expanded regulatory approvals for broader transplant applications.
Related topics